Welcome Anahita Nimbalkar
Welcome to Anahita Nimbalkar who joins our group as a research technician.
Author: Lia Limone
Welcome Grace Kelley
Welcome to Grace Kelley who joins our group as a research technician on the model development team.
Emily Hensley, B.A.
Emily joined the Hata Lab in June 2022 after receiving her BA from College of the Holy Cross. At Holy Cross, Emily was a Biology/Chinese double major, and worked in Dr. Alexis Hill’s Drosophila Neurobiology lab. Her work focused on the gene seizure (sei) and how it affects developmental time in Drosophila, along with determining which cell types express sei. In the Hata lab, she is a member of the Model Development Team which seeks to create cell lines and PDX models from patient lung cancer samples. Outside of lab, Emily enjoys doing ballet, playing with her cat, and spending time with friends and family.
Welcome Emily Hensley
Welcome to Emily Hensley who joins our group as a research technician on the model development team.
Farewell Usman
We say farewell to Usman who is attending the University of Rochester for an MD-PhD program. Best wishes to you in your future endeavors – we will miss you!
Lungstrong 5K
The return of the 9th Annual Lungstrong 5K as a live and in person event was a success – thanks to everyone who came out to run and walk in support of lung cancer research at MGH!
Toshio Fujino, MD-Ph.D.
Toshio joined the Hata Lab in April 2022. He received his MD at Nagoya City University, Japan and practiced as a thoracic surgeon in Japan, where he developed a great interest in cancer biology. He then obtained his Ph.D. at Kindai University, Japan, where he studied the resistance mechanism to MET-TKIs in lung cancer harboring MET exon 14 skipping mutation in the laboratory of Dr. Tetsuya Mitsudomi. Toshio is currently focusing on drug persister cancer cell and acquired resistance to targeted therapies especially in ALK-positive lung cancer. Despite of the initial drastic efficacy of molecular targeted therapy, all patients inevitably develop resistance. Toshio believes that his project will contribute to establish new treatment strategies for lung cancer to prevent the drug resistance.
Farewell Linh
We say farewell to Linh who is a MD-PhD Candidate at Thomas Jefferson University. Best wishes to you in your future endeavors – we will miss you!
2022 AACR Annual Meeting News
2022 AACR Annual Meeting News: Kipp Weiskopf, Whitehead Fellow at MIT, presented a poster “Targeted therapies prime lung cancer cells for macrophage-mediated destruction” highlighting work done in collaboration with the Hata Lab that suggests that blocking CD47 on tumor cells may improve the response to lung cancer targeted therapies.
2022 AACR Annual Meeting
The Hata lab was well represented with two oral presentations at the 2022 AACR Annual Meeting in New Orleans. Hideko Isozaki presented “Impact of therapy induced APOBEC3A mutagenesis on tumor evolution in non small cell lung cancer” highlighting a new mechanism by which targeted therapies may induce mechanisms that facilitate evolution of acquired resistance. Chendi Li presented “LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRAS G12C + MCL-1 blockade,” describing a novel mechanism by which LKB1 loss leads to a targetable therapeutic vulnerability in KRAS mutant lung cancers and providing rationale for clinical testing of KRAS G12C + MCL-1 inhibitors in this patient population.”
